Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00616889|
Recruitment Status : Completed
First Posted : February 15, 2008
Last Update Posted : December 16, 2015
|Condition or disease||Intervention/treatment|
|Bipolar Disorder||Drug: Seroquel|
To assess the objective (polysomnographic) change in sleep quality before and after introduction of Seroquel (Quetiapine) in treatment of patients with Bipolar Depression or Major Depressive Disorder.
To assess the objective (polysomnographic) and subjective changes in sleep quality parameters before and at different stages after introduction of Seroquel (Quetiapine) treatment, longitudinally, and to correlate these changes with measures of illness severity.
Prospective polysomnographic (PSG) study of patients before and after treatment with Seroquel (Quetiapine). PSG recordings will be done three (optional four) times during the study: before starting the Seroquel (Quetiapine) (baseline), at day 2 to 4 (early) and day 21 to 28 (longer term). (Optional fourth PSG can be done at day 42-56). PSG will be completed at patients home with a portable PSG.
|Study Type :||Observational|
|Actual Enrollment :||15 participants|
|Official Title:||Effects of Seroquel on Sleep Architecture in Patients With Bipolar Depression or Major Depressive Disorder - An Open Label Study|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||January 2009|
Seroquel added to medication regime and sleep quality measured
The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
Other Name: Quetiapine
- Sleep quality as measured by overnight PSG. [ Time Frame: baseline, day 2 to 4 (early) and day 21 to 28 (longer term). Optional reading at day 42-56 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00616889
|Kingston, Ontario, Canada, K7L 4X3|
|Principal Investigator:||Roumen V Milev, MD||Queen's University|